庚二亚氨酸二甲酯二盐酸盐 | 58537-94-3

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 中文名称: 庚二亚氨酸二甲酯二盐酸盐
• 中文别名: 庚二酰亚胺酸二甲酯二盐酸盐
• 英文名称: Dimethyl pimelimidate dihydrochloride
• 英文别名: dimethyl heptanediimidate;dihydrochloride
• CAS: 58537-94-3
• 化学式: C9H20Cl2N2O2
• mdl: MFCD00038942
• 分子量: 259.17
• InChiKey: LRHXBHUTQWIZTN-UHFFFAOYSA-N

物化性质

• 熔点：
  ~122 °C (dec.)
• 溶解度：
  在水中的溶解度10mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  1.19
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  66.2
• 氢给体数：
  4
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25
• 危险类别码：
  R38
• WGK Germany：
  3
• 海关编码：
  29252900
• 危险性防范说明：
  P280
• 危险性描述：
  H315

制备方法与用途

制备方法

化学试剂

用途简介 用途

化学试剂

文献信息

• Cobalamin conjugates for anti-tumor therapy
  申请人：Weinshenker M. Ned

  公开号：US20050054607A1

  公开（公告）日：2005-03-10

  The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5′-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells. The conjugate of the invention advantageously provides a reduced systemic toxicity and enhanced efficacy as compared to a corresponding free drug.

  本发明提供了一种适用于治疗肿瘤相关疾病的钴胺素-药物结合物。钴胺素通过可切割的连接剂间接共价结合到抗肿瘤药物上，还可以通过一个或多个可选的间隔物。钴胺素通过其核糖环的5'-OH与第一间隔物或可切割连接剂共价结合。药物通过其现有或添加的功能基团与可切割连接剂的第二间隔物结合。在给药后，结合物与转钴胺素（其任何同工异构体）形成复合物。然后，该复合物结合到细胞膜上的受体并被细胞摄取。一旦进入细胞，细胞内酶将切割结合物，从而释放药物。根据结合物的结构，特定类别或类型的细胞内酶影响切割。由于生长细胞对钴胺素的需求量较高，肿瘤细胞通常摄取结合物的比例高于正常非生长细胞。本发明的结合物与相应的游离药物相比，具有较低的全身毒性和增强的疗效。
• PDE4B inhibitors
  申请人：Ibrahim N. Prabha

  公开号：US20060100218A1

  公开（公告）日：2006-05-11

  Compounds are described that are active on PDE4. Also described are crystal structures of PDE4B determined using X-ray crystallography, the use of PDE4B crystals and strucural information for identifying molecular scaffolds, for developing ligands that bind to and modulate PDE4B, and for identifying improved ligands based on known ligands.

  描述了对PDE4活性的化合物。还描述了使用X射线晶体学确定的PDE4B的晶体结构，利用PDE4B晶体和结构信息来识别分子支架，开发结合和调节PDE4B的配体，并根据已知配体来识别改进的配体。
• PDE4B inhibitors and uses therefor
  申请人：Ibrahim N. Prabha

  公开号：US20060041006A1

  公开（公告）日：2006-02-23

  Compounds active on phosphodiesterase PDE4B are provided. Also provided herewith are compositions useful for treatment of PDE4B-mediated diseases or conditions, and methods for the use thereof.

  提供对磷酸二酯酶PDE4B活性的化合物。还提供了用于治疗PDE4B介导的疾病或症状的组合物，以及其使用方法。
• Compounds and methods for development of Ret modulators
  申请人：Ibrahim Prabha

  公开号：US20070049615A1

  公开（公告）日：2007-03-01

  Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and strucural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.

  描述了对Ret具有活性的化合物，以及使用这些化合物的方法。还描述了通过X射线晶体学确定的Ret替代物的晶体结构。例如，使用这些Ret替代物晶体和结构信息可以用于识别分子支架，开发与Ret结合并调节其活性的配体，以及基于已知配体识别改进的配体。
• Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof
  申请人：MacKinnon Roderick

  公开号：US20050272093A1

  公开（公告）日：2005-12-08

  Assays for screeing potential drugs or agents that can interact and potentially bind to cation channel proteins, and potentially have uses in treating conditions related to the function of cation channel proteins is provided, along with prokaryotic cation channel proteins mutated to mimic eukaryotic cation channels, which can then be used in assays of the present invention.

  提供了用于筛选可能与阳离子通道蛋白相互作用并潜在结合的潜在药物或药剂的检测方法，并且提供了突变成模拟真核细胞阳离子通道的原核细胞阳离子通道蛋白，这些蛋白可以用于本发明的检测方法。